The Performance of Patient Support Program in Early Stage Breast Cancer
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00769080
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to compare the 1-year adherence to upfront adjuvant AI for postmenopausal, early stage breast cancer in the two observational arms; Standard Treatment and Standard Treatment plus PSP arm after one year
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 524
Inclusion Criteria
- Provide signed and dated written Informed Consent
- Have been taking upfront AI adjuvant therapy in line with current SmPC
- Be capable of completing drug intake by herself
- Be capable of understanding Chinese
Exclusion Criteria
- Upfront adjuvant hormonal therapy by an AI to which upfront adjuvant indication has not been granted by SFDA
- Upfront adjuvant AI medication which has exceeded over eight weeks
- Previous adjuvant hormonal therapy for breast cancer lasting over 8 weeks other than AI
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method compare the 1-year adherence 1 year
- Secondary Outcome Measures
Name Time Method scores of Beliefs about Medicines Questionnaire (BMQ) 1 year Scores in Patient Centred Care Questionnaire (PCCQ) 1 year Morisky scale 1 year
Trial Locations
- Locations (1)
Research Site
🇨🇳Hangzhou, Zhejiang, China